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Abstract
Amyloid diseases represent a growing social and economic burden in the developed world. Understanding the assembly
pathway and the inhibition of amyloid formation is key to developing therapies to treat these diseases. The neurodegen-
erative condition Machado–Joseph disease is characterised by the self-aggregation of the protein ataxin-3. Ataxin-3 consists
of a globular N-terminal Josephin domain, which can aggregate into curvilinear protofibrils, and an unstructured, dynam-
ically disordered C-terminal domain containing three ubiquitin interacting motifs separated by a polyglutamine stretch.
Upon expansion of the polyglutamine region above 50 residues, ataxin-3 undergoes a second stage of aggregation in which
long, straight amyloid fibrils form. A peptide inhibitor of polyglutamine aggregation, known as polyQ binding peptide 1, has
been shown previously to prevent the maturation of ataxin-3 fibrils. However, the mechanism of this inhibition remains
unclear. Using nanoelectrospray ionisation-mass spectrometry, we demonstrate that polyQ binding peptide 1 binds to
monomeric ataxin-3. By investigating the ability of polyQ binding peptide 1 to bind to truncated ataxin-3 constructs lacking
one or more domains, we localise the site of this interaction to a 39-residue sequence immediately C-terminal to the
Josephin domain. The results suggest a new mechanism for the inhibition of polyglutamine aggregation by polyQ binding
peptide 1 in which binding to a region outside of the polyglutamine tract can prevent fibril formation, highlighting the
importance of polyglutamine flanking regions in controlling aggregation and disease.
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Introduction
Polyglutamine (polyQ) expansion diseases comprise a
group of nine inherited protein aggregation disorders
characterised by the deposition of proteins containing
aberrantly expanded polyQ domains into amyloid
ﬁbrils.1 These disorders are characterised by a polyQ-
length dependence on the age of onset of diseases, in
which the age of disease onset correlates inversely with
polyQ length.1 A diﬀerent protein is involved in each
disease within this class and the length of the polyQ
domain required for ﬁbril formation in vitro and
disease onset varies, indicating that the sequence and
context of the polyQ domain play an important role in
determining aggregation propensity. Consistent with
this, there is no sequence homology between the diﬀer-
ent proteins involved in polyQ aggregation disorders
outside of their polyQ domains,1 and numerous bio-
chemical and biophysical studies in vitro have shown
the importance of the sequences ﬂanking the polyQ
tract in determining its aggregation propensity.2–7
Machado–Joseph disease (MJD) is a member of the
family of polyQ expansion diseases.8 In this disorder,
disease occurs with the expansion of the polyQ domain
beyond a threshold of 50 glutamine residues.8,9 Ataxin-
3 is comprised of an N-terminal 21 kDa globular
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Josephin domain (JD) followed by two ubiquitin inter-
acting motifs (UIM), a polyQ domain and, depending
on the isoform, a third UIM.10 Each of these domains
is linked by disordered regions of varying length
(Figure 1(a)).
In vitro, the JD in isolation can undergo aggregation
to form thioﬂavin-T (ThT) positive amyloid protoﬁ-
brils.11,12 However, the presence of an expanded
polyQ domain of >50 residues is required for matur-
ation of the protoﬁbrils into long straight ﬁbrils typical
of amyloid in a subsequent polyQ-dependent stage
(Figure 2).11 Although an NMR structure has been
solved for the N-terminal JD,13 little is known about
the structure of the primarily disordered C-terminal
‘tail’ apart from the UIMs, which comprise two short
a-helices.14 Despite detailed kinetic analyses of the
aggregation of ataxin-3,11,15–18 why and how this pro-
tein undergoes two-phase aggregation remain unclear.
Screening of libraries for peptides able to bind to
polyQ fusion proteins resulted in the discovery of an
11-residue sequence named polyQ binding peptide 1
(QBP1).19 QBP1 has been shown to be an eﬀective
inhibitor of polyQ aggregation both in vitro19–22 and
in vivo.23–25 Surface plasmon resonance studies com-
paring the binding of QBP1 and Congo Red to a
range of thioredoxin polyQ fusion proteins suggested
that whereas Congo Red exhibits non-speciﬁc binding
independent of the polyQ stretch, QBP1 binds speciﬁc-
ally to the polyQ domain.26 However, as the thiore-
doxin-polyQ fusion protein is a non-disease protein,
it has been suggested that this ﬁnding may not be sig-
niﬁcant to polyQ pathology.27 Other studies have also
suggested that QBP1 interacts with polyQ protein
monomers and prevents their pre-oligomerisation
b-sheet conformational switch.28 Previous work has
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Figure 1. The architecture of ataxin-3. Ataxin-3 constructs used in these studies consist of a globular N-terminal domain (the JD, residues
1–182) and a largely disordered C-terminal tail containing three UIMs plus a polyQ domain. The constructs used are (a) ataxin-3 78Q;
(b) ataxin-3 14Q; (c) JDU1, the JD plus the first UIM (residues 1–241); (d) JDþ, the JD plus residues 183–221, (e) the JD alone (residues
1–182) and (f) MBPþ, maltose binding protein linked to residues 183–221 of ataxin-3, separated by a TEV cleavage site. All ataxin-3
constructs (a–d) contain an N-terminal hexahistidine tag followed by a TEV cleavage site (LENLYFQG).
JD: Josephin domain; UIMs: ubiquitin interacting motifs; polyQ: polyglutamine; MBP: maltose binding protein; TEV: Tobacco Etch Virus
protease.
QBP1
14 Q
78 Q
Josephin Domain
Ubiquitin interacting motif
PolyQ stretch
Mature Fibril
Protofibril
Figure 2. Ataxin-3 aggregation mechanism. Ataxin-3 aggregation
proceeds by a two-step process: all ataxin-3 constructs undergo a
Josephin domain-mediated initial aggregation step to produce
protofibrils. However, only protofibrils derived from ataxin-3 with
>55Q residues in the polyQ domain undergo the second step, a
rearrangement which produces long, straight amyloid fibrils. The
presence of the peptide QBP1 does not affect the first stage of
aggregation, but inhibits the polyQ-dependent step.11
polyQ: polyglutamine; QBP1: polyQ binding peptide 1.
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demonstrated that QBP1 inhibits the polyQ-dependent
stage of ataxin-3 aggregation, while having no eﬀect on
polyQ-independent aggregation (Figure 2), but how the
two species interact remained unknown.11 There is evi-
dence for the eﬃcacy of QBP1 as a therapeutic against
amyloid disease in animal models;23–25 however, the
lack of understanding of the mechanism of inhibition
is one hurdle preventing the application of QBP1 or
similar peptides as possible leads for the development
of much-needed agents able to combat polyQ-related
diseases.
Here we use nanoelectrospray ionisation-(ion mobil-
ity spectrometry)-mass spectrometry (ESI-(IMS)-MS)
to examine the interaction of QBP1 with a series of
ataxin-3 constructs that contain, or lack, diﬀerent
domains in order to identify the binding site(s) of the
peptide for this polyQ-containing protein (Figure 1).
The results demonstrate that QBP1 binds to monomers
of ataxin-3 (78Q and 14Q) in a stoichiometric ratio.
Surprisingly, similar binding was observed to truncated
ataxin-3 variants lacking a polyQ domain, indicating
that suppression of the polyQ-dependent stage of
aggregation does not result from direct binding to the
polyQ tract. Using truncation variants of ataxin-3, we
identify a novel binding site for QBP1 as a 39-residue
sequence immediately C-terminal to the JD. The results
add insight into the nature of the conformational
changes required for ﬁbril formation of ataxin-3 and
reinforce the ﬁndings in other systems that the aggre-
gation of polyQ domains is highly dependent upon
their ﬂanking regions.2–7
Experimental details
Protein and peptide preparation
Ataxin-3 containing diﬀerent polyQ lengths (ataxin-3
78Q and ataxin-3 14Q) and the truncated JD constructs
(Figure 1) were expressed and puriﬁed as described pre-
viously.12 JDU1 and JDþ were created by placing a
stop codon in the gene encoding ataxin-3 14Q using
Q5 Quikchange mutagenesis (New England Biolabs
Ltd., Herts., UK) and the primers shown in
Supplementary Table 1. Sequences were inserted into
the gene encoding ataxin-3 78Q within pET11a plas-
mids and proteins expressed in BL21(DE3)pLysS cells
at 25C by auto induction.12 Protein expression was
allowed to continue for 22 h, after which time bacteria
were harvested. The ataxin-3 constructs were then pur-
iﬁed using nickel aﬃnity chromatography followed by
size exclusion chromatography (S200 column) to create
pure monomeric proteins. The resulting constructs are
shown in schematic form in Figure 1.
The maltose binding protein (MBP) fusion protein
was generated by appending the sequence for ataxin-3
residues 183–221 to the C-terminus of MBP with a TEV
protease cleavable linker. Dr David Brockwell
(University of Leeds) kindly provided a modiﬁed
pMAL-c5X (New England Biolabs Ltd., Herts., UK)
plasmid containing the BamA POTRA domains with
the addition of an N-terminal 6 x His-tag (HT) and
replacement of the thrombin cleavage site with a TEV
cleavage site. Residues 183–221 of ataxin-3 were excised
from the gene encoding ataxin-3 14Q using polymerase
chain reaction (PCR), and then inserted in place of the
BamA POTRA domains. The resulting construct was
named MBP-183–221.
The UIM peptides 222–241 and 222–264 were pur-
chased from Bachem AG (Bubendorf, Switzerland).
N-terminally acetylated QBP1 (AcSNWKWWPGIFD)
was purchased from Bio-Synthesis Inc. (Lewisville,
TX, USA).
PolyQ aggregation assays
Aggregation of the diﬀerent ataxin-3 constructs was
assayed by monitoring the ﬂuorescence of ThT.
Samples (10 mM protein) in the presence or absence of
50 mM QBP1 were mixed with 20 mM ThT in 250mM
ammonium hydrogen carbonate, 1mM dithiothreitol,
pH 7.8. In all, 100 mL of sample was added to a single
well of a 96-well plate (catalogue number 3881,
Corning, Sigma-Aldrich, Dorset, UK). Fluorescence
was monitored using a FluoStar Optima or Omega
plate reader (BMG Labtech, Aylesbury, Bucks, UK).
Excitation was at 440 nm and emission was read at
475 nm. The plate was held at 37C without shaking
for the duration of the experiments.
Negative stain transmission electron micrographs
(EMs) of the end point of the ﬁbrillation reaction
(51 h) were acquired using a JEM 1400 transmission
electron micrograph (JEOL Ltd., Tokyo, Japan).
Samples were pipetted onto Formvar-carbon grids
and negatively stained with 4% (w/v) uranyl acetate.
1H-nuclear magnetic resonance
T1r experiments were performed on samples contain-
ing 50 mM QBP1 in 250mM ammonium hydrogen
carbonate, 10% (v/v) D2O and 10 mM protein. Data
were acquired on a 600MHz NMR magnet (Oxford
Instruments, Abingdon, UK) using a QCI-P-cryoprobe
and an Avance III HD console (Bruker Corpn.,
Coventry, UK) using a 100ms spin-lock. The data
were acquired and processed with Bruker TopSpin,
NMRPipe and CcpNMR analysis software.
Nano-ESI-(IMS)-MS
ESI-(IMS)-MS experiments were performed on a
Synapt HDMS Q-ToF instrument equipped with
travelling wave IMS situated between the two analysers
(Waters UK Ltd., Wilmslow, Cheshire, UK). Samples
were prepared as 10 mM protein and 50 mM QBP1
in 250mM ammonium hydrogen carbonate, 1mM
dithiothreitol, pH 7.8. The samples were infused
via gold-palladium coated borosilicate nano-capillaries
fabricated in-house. Typical instrument settings
Knight et al. 131
were: capillary voltage 1.5–1.7 kV, sampling cone 60V,
trap collision energy 15V and transfer collision energy
25V. Calibration of the m/z range was achieved on NaI
clusters (2mg/mL 1:1 v/v propan-2-ol:water NaI). Data
were acquired, processed and visualised using the soft-
ware provided with the instruments (MassLynx 4.1 and
Driftscope 2.5).
Ion mobility data were acquired simultaneously with
MS measurements. Travelling wave IMS calibration
was performed using a range of standards from the
published list of protein calibrants.29 The speciﬁc cali-
brants used here were cyctochrome C, concanavalin A,
b-lactoglobulin, alcohol dehydrogenase and avidin.
Each protein calibrant was analysed three times and
the average collision cross-section (CCS) calculated.
Results
Ataxin-3 aggregation inhibition by QBP1 is
maintained in volatile solvents
The progress of aggregation of ataxin-3 78Q in the
presence or absence of a ﬁve-fold molar excess of
QBP1 in the ESI-MS compatible buﬀer, 250mM
ammonium hydrogen carbonate, pH 7.8 is shown in
Figure 3. Consistent with previous results,11,12 aggrega-
tion proceeds via a ThT-sensitive phase, which results
in the formation of protoﬁbrils, followed by a ThT-
insensitive second phase in which the ﬁnal long, straight
amyloid ﬁbrils form (Figure 3, inset). As expected,11
addition of QBP1 to ataxin-3 78Q had no eﬀect on
the formation of protoﬁbrils, as measured by the ThT
ﬂuorescence assay, but prevented conversion to mature
ﬁbrils (Figure 3). Thus, the aggregation processes of
ataxin-3, and the inhibition of these processes by
QBP1, are maintained under MS-amenable conditions.
ESI-MS reveals a novel binding site for QBP1
and ataxin-3 independent of the polyQ tract
To determine how QBP1 prevents amyloid ﬁbril forma-
tion of ataxin-3 78Q, the ability of diﬀerent variants,
lacking one or more domains, to bind QBP1 was ana-
lysed using ESI-MS. The native ESI mass spectrum of
ataxin-3 78Q is shown in Figure 4(a). The spectrum
reveals that under the conditions employed ataxin-3
78Q is primarily monomeric (all theoretical and
observed masses are detailed in Supplementary Table
2), and results in two charge state distributions arising
from compact ((Mþ 14H)14þ to (Mþ 20H)20þ) and
more expanded ((Mþ21H)21þ) conformations, con-
sistent with previous results (Figure 4(a)).12,30 Such
proﬁles tend to indicate the protein’s conformational
characteristics in solution.31 The addition of QBP1 to
ataxin-3 78Q leads to the formation of a 1:1 complex
between the peptide and protein (Supplementary
Table 2) (Figure 4(b)). No further binding was observed
when the concentration of QBP1 was raised to a 16-fold
molar excess suggestive of speciﬁc binding (data not
shown). Additionally, QBP1 was found to bind only
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Figure 3. Self-assembly of ataxin-3 78Q monitored by ThT fluorescence. Protein aggregation was measured in the absence (black solid
circles) or presence (blue open circles) of a five-fold molar excess of QBP1. After a lag-time of 5 h, protofibrils form which then convert
into amyloid fibrils (inset top: TEM image). In the presence of the peptide inhibitor QBP1, the ataxin-3 protofibrils form (blue open circles)
but do not convert into full-length amyloid fibrils (inset lower: TEM image). Both TEM images were taken at t¼ 51 h.
ThT: thioflavin-T; QBP1: polyQ binding peptide 1; TEM: transmission electron micrograph.
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Figure 5. QBP1 interacts with ataxin-3 constructs lacking a polyQ domain, but not with the JD alone. ESI mass spectra of (a) ataxin-3 14Q
(mass 43,451.3 Da; mass of 1:1 complex 14Q:QBP1, 44,929.1 Da); (b) ataxin-3 residues 1–241 (JDU1) (mass 30,046.7 Da; mass 1:1 complex
JDU1:QBP1, 31,522.5 Da); and (c) the JD alone (ataxin-3 residues 1–182, mass 23,237.2 Da), each in the presence of a five-fold molar excess
of QBP1. Peaks corresponding to 1:1 complexes of protein: QBP1 are shown in blue. Masses of all proteins and their complexes are shown
in Supplementary Table 2.
QBP1: polyQ binding peptide 1; polyQ: polyglutamine; JD: Josephin domain.
2500 3000 3500
%
100
0
1
17+
1
16+
1
15+
1
14+
1
18+
1
19+
1
20+
1
21+1
22+
1
23+
1
24+
1
25+
m/z
2500 3000 3500
%
100
0
1PBQ
+1
+51
1
17+
1
16+
1
15+
1
14+
1
18+
1
19+
1
20+1
21+1
22+1
23+1
24+1
25+
1PBQ
+1
+611PBQ
+1
+ 711PBQ
+1
+81
1PBQ
+1
+91
1PBQ
+1
+02
Ataxin-3 78Q
(a)
(b)
+QBP1
Figure 4. QBP1 binds to compact conformers of ataxin-3 78Q. ESI mass spectra of (a) ataxin-3 78Q (51,751.0 Da; black peaks) and (b)
ataxin-3 78Q in the presence of a five-fold molar excess of QBP1 (mass 1477.6 Da). The peaks corresponding to a 1:1 ataxin-3 78Q: QBP1
complex (53,228.6 Da) are shown in blue. Masses of all proteins and their complexes are shown in Supplementary Table 2.
QBP1: polyQ binding peptide 1; ESI: electrospray ionisation.
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Figure 6. Solution-phase 1H-NMR confirms QBP1 binds to ataxin-3 78Q, ataxin-3 14Q, JDU1 and JDþ, but not JD. T1r NMR spectra for
QBP1 alone (black) and in the presence of (a) ataxin-3 78Q (red), (b) ataxin-3 14Q (green), (c) ataxin-3 residues 1–241 (JDU1; blue), (d)
ataxin-3 residues 1–221 (JDþ; purple) and (e) the Josephin domain alone residues 1–183 (JD; orange). A reduction in signal intensity (a–d)
indicates an interaction between the peptide and the protein.
NMR: nuclear magnetic resonance; QBP1: polyQ binding peptide 1.
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to the more compact conformers of ataxin-3 78Q (i.e. to
the 14þ to 20þ charge state ions), while no binding was
observed for the more highly charged ions (21þ).
Given that QBP1 was selected against a 62-residue
polyQ sequence19 and has been shown not to bind
polyQ segments of 19 residues in length,26 the ability
of QBP1 to bind ataxin-3 of non-pathological length
(14Q; Figure 1(b)) was tested next using ESI-MS. The
results (Figure 5(a)) showed that ataxin-3 14Q is also
able to bind to QBP1, with a 1:1 binding stoichiometry
(Supplementary Table 2) being observed both when a
ﬁve-fold (Figure 5(a)) and 16-fold (Supplementary
Figure 1) excess of peptide are added. Similar to its
longer polyQ counterpart, only the more compact of
the two protein conformer populations observed was
found to bind to QBP1.
Further investigations using a truncation variant of
ataxin-3 comprising the JD with UIM1 only (i.e. resi-
dues 1–241) (JDU1; Figure 1(c)), revealed that the dele-
tion of all residues C-terminal to the UIM does not
alter binding (Figure 5(b) and Supplementary Table
2). This construct does not contain a polyQ tract,
revealing the surprising results that a polyQ domain is
not required for QBP1 binding. Importantly, a complex
between QBP1 and the JD alone (consisting of residues
1–182; Figure 1(e)) was not observed (Figure 5(c) and
Supplementary Table 2), conﬁrming the speciﬁcity of
binding to JDU1 and the longer ataxin-3 constructs.
Together, the results suggest that QBP1 binds to resi-
dues 183–241 of ataxin-3. Given that a 1:1 complex
is observed for all of the constructs which bind QBP1,
even when an excess of peptide is added, it is likely that
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Figure 7. Ataxin-3 residues 183–221 are sufficient for QBP1 binding. ESI mass spectra of QBP1 (mass 1477.6 Da) with (a) a synthetic
peptide equivalent to residues 222–241 (UIM1) of ataxin-3 (mass 2358.5 Da; mass of 1:1 complex UIM1:QBP1, 3836.1 Da; (b) a synthetic
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presence of a five-fold molar excess of the peptide QBP1. Peaks corresponding to a 1:1 complex JDþ:QBP1 (mass 29,182.2 Da) are shown
in blue. Peaks corresponding to a 1:1 complex of protein dimer to QBP1 (mass 56,886.4 Da) are shown in red. Masses of all proteins and
their complexes are given in Supplementary Table 2.
QBP1: polyQ binding peptide 1; ESI: electrospray ionisation.
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the same binding site is mediating the interaction in all
of the constructs.
To support the unexpected observation that QBP1
binds to a region of ataxin-3 distant to the polyQ
region, T1r NMR experiments were performed to pro-
vide orthogonal, solution-phase information. In the
T1r experiment, binding of a low molecular mass
ligand to a high molecular mass partner results in line
broadening (and therefore loss of signal intensity) due
to the increased ‘tumbling time’ of the ligand in the
complex in a manner that depends on the exchange
rate and the size of the complex.32 The T1r technique
is particularly sensitive for weak interactions where
chemical shift perturbations upon binding are not
observed due to the low population of the complex.
After integration of the resonances arising from the
methyl region of the T1r spectrum (0.45–0.75 ppm),
the results of these experiments showed an attenuation
of the peptide signals when QBP1 is bound to ataxin-3
78Q (24% loss of signal; Figure 6(a)), ataxin-3 14Q
(22% signal loss; Figure 6(b)), JDU1 (14% signal
loss; Figure 6(c)) and JDþ (8% signal loss; Figure
6(d)), but no loss in signal when QBP1 was mixed
with JD alone (Figure 6(e)). The decreased eﬀect of
signal attenuation shown in Figure 6(a) to (d) is con-
sistent with the decreasing molecular weight of these
complexes in comparison to ataxin-3 78Q. These
experiments thus show that QBP1 binds to the ataxin-
3 constructs ataxin-3 78Q, ataxin-3 14Q, JDU1 and
JDþ in solution, as well as retaining their bound state
in the gas-phase.
Residues 182–221 of ataxin-3 bind QBP1
The results presented above indicate that while the JD
(residues 1–182) does not bind QBP1 (Figure 5(c)),
extension of this construct by the addition of residues
183–241 (JDU1; Figure 1(c)) restores the ability of the
protein to bind QBP1 (Figure 5(b)). The region
183–241 must thus confer binding. This region contains
a 39-residue disordered sequence followed by the ﬁrst
UIM of ataxin-3 (Figure 1). Interestingly, previous stu-
dies of ataxin-333,34 have suggested that UIMs can be
involved in the aggregation process and may inhibit
aggregation of polyQ proteins. Binding of QBP1 to
this region may thus prevent conformational changes
required for conversion of protoﬁbrils into fully
assembled amyloid ﬁbrils involving self-association of
the polyQ region.
To explore whether the UIMs of ataxin-3 confer
binding to QBP1, ESI-MS was carried out on peptides
comprising the sequence of the ﬁrst UIM (residues 222–
241; UIM1) of ataxin-3, or the ﬁrst and second UIMs
(residues 222–264; UIM12), in the absence or presence
of equimolar QBP1. These experiments (Figure 7(a)
and (b)) showed no evidence for any interaction
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Figure 8. Residues 183–221 of ataxin-3 bind QBP1. (a) ESI mass spectrum of the construct of MBP-183–221 (mass 49,207.6 Da) in the
presence of equimolar QBP1 (mass 1477.6 Da). Peaks corresponding to a 1:1 complex of protein:QBP1 (mass 50,685.2 Da) are shown in
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cleavage site (see Methods). (b) ESI mass spectrum of the TEV-cleaved Maltose Binding Protein ataxin-3 183–221 fusion protein (mass
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MBP-183–221 following cleavage of residues 183–221. Masses of all proteins and their complexes are given in Supplementary Table 2.
QBP1: polyQ binding peptide 1; ESI: electrospray ionisation; MBP: maltose binding protein.
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between these peptides and QBP1, despite the peptides
adopting helical structure (revealed by far UV CD;
Supplementary Figure 2 and Table 3) consistent with
their native structure. Conversely, an ataxin-3 construct
(residues 1–221) which contains the JD and the sub-
sequent 39-residue disordered sequence (JDþ,
Figure 1(d)) was found to interact with QBP1, forming
a 1:1 complex as was observed for the longer ataxin-3
constructs (Figure 7(c) and Supplementary Table 2).
The data from these experiments suggest that resi-
dues 183–221 are necessary and suﬃcient for inter-
action of ataxin-3 with QBP1. To examine whether
residues 183–221 alone are suﬃcient for binding, inde-
pendent of the JD, the sequence 183–221 of ataxin-3
was appended C-terminally to MBP separated by a
TEV cleavage site (Figures 1(f) and 8, inset). MBP pro-
vides a stable solubilisation domain and has been used
previously in the investigation of truncated ataxin-3
constructs.36 Remarkably, native ESI-MS of this pro-
tein (MBP-183–221) in the presence of QBP1 resulted in
a 1:1 complex (Figure 8(a) and Supplementary Table 2).
Treatment with TEV protease to remove the ataxin-3-
derived residues abrogated the QBP1 interaction, indi-
cative of a speciﬁc interaction between residues 183–221
of ataxin-3 and QBP1 (Figure 8(b)). These data dem-
onstrate that residues 183–221 are both necessary and
suﬃcient for interaction with QBP1 and that this bind-
ing competence is maintained even when the residues
are removed from their native protein context.
QBP1 binding does not alter ataxin-3 conformation
Several inhibitors of amyloid aggregation have been
shown to alter the conformation of the bound
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Figure 9. ESI-(IMS)-MS indicates that ataxin-3 78Q does not undergo any significant change in CCS upon binding QBP1. (a) ESI-(IMS)-MS
arrival time distribution for the 17þ charge state ions of (i) ataxin-3 78Q alone, and (ii) ataxin-3 78Q:QBP1 1:1 complex; (b) CCS calculated
from ESI-(IMS)-MS data for 13þ to 20þ charge state ions for ataxin-3 78Q alone (white circles) and the ataxin-3 78Q:QBP1 complex (blue
circles). n.b. The CCS measurements for the 15+ and 16+ ions of ataxin-3 78Q and ataxin-3 78Q:QBP1 complex are indistinguishable.
ESI-(IMS)-MS: electrospray ionisation-(ion mobility spectrometry)-mass spectrometry; CCS: collision cross-section; QBP1: polyQ binding
protein 1.
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protein.37 To investigate whether this is the case for the
QBP1:ataxin-3 complex observed here, ESI-(IMS)-MS
was used to measure the CCS of ataxin-3 78Q in the
absence or presence of QBP1. The CCS can be mea-
sured from the IMS-MS data based on the feature that
ions of the same charge and m/z will be separated if
their physical size diﬀers, with the larger ions travelling
more slowly through the gas-ﬁlled IMS cell.29,38,39 The
results showed a very similar arrival time distribution
for the 17þ ions for both ataxin-3 78Q and the ataxin-3
78Q:QBP1 complex (Figure 9(a)). Indeed, across all
charge states the CCS values for bound and unbound
protein are not signiﬁcantly diﬀerent (Figure 9(b)).
Similar results were observed for all other ataxin-3 con-
structs able to bind QBP1 (Supplementary Figure 3).
Thus, at least as measured by ESI-(IMS)-MS, no sub-
stantial alterations in the conformational properties of
the disordered ‘tail’ of ataxin-3 occur when QBP1 binds
to the region 183–221.
Conclusions
Searching for inhibitors of protein aggregation is essen-
tial to elucidate in more detail how proteins self-assem-
ble into amyloid ﬁbrils, and to further our
understanding of how protein aggregation causes dis-
ease. The peptide QBP1 is one such inhibitor, which
was selected against polyQ-containing proteins19 and
shown to inhibit the aggregation of polyQ fusion pro-
teins and ataxin-3 in vitro and in vivo.11,19–25,28 Here we
present the surprising ﬁnding that while QBP1 prevents
amyloid formation of ataxin-3 78Q, it does so via a
novel binding site that is distal to the polyQ tract. By
creation of a series of ataxin-3 constructs in which each
protein diﬀers by one or more domains (Figure 1), and
analysis of the ability of the resulting constructs to bind
QBP1 using ESI-MS, we show that ataxin-3 residues
183–221 are both necessary and suﬃcient for binding
to QBP1. This region has not previously been con-
sidered to have a role in QBP1 binding. Importantly,
since only 1:1 binding is observed even in the presence
of a 16-fold molar excess of peptide, the results pre-
sented suggest that while expanded polyQ can bind
QBP1, such binding must be precluded in the ataxin-3
proteins studied here. This eﬀect may be caused by con-
formational changes in which the region 183–221
occludes the polyQ binding site, although such a
change is not detectable using IMS-MS, possibly
because the overall size of the protein does not alter
signiﬁcantly, or because of structural changes in this
intrinsically disordered region in the gas-phase.40
Nonetheless, the results presented support a model in
which the region 183–221 plays a vital role in the pro-
gression of ataxin-3 aggregation from the JD-depen-
dent initial phase of protoﬁbril formation to the
second stage in which polyQ-dependent amyloid ﬁbrils
form (Figure 2). The importance of residues distant
from the polyQ domain in mediating aggregation
reiterates existing evidence for the importance of
ﬂanking regions of polyQ-containing proteins upon
their aggregation into amyloid. For example, it has
been demonstrated that the JD plays an important
role in polyQ-dependent aggregation of ataxin-3.18,41
For other polyQ proteins, the sequence context of a
polyQ domain has also been shown to inﬂuence the
threshold at which the protein becomes a pathogenic
expansion.1
While residues 183–221 of ataxin-3 have not been
considered previously as possible binding sites for
QBP1, there is literature precedent for the involvement
of this region in ataxin-3 aggregation. The so-called
‘central ﬂexible region’ of ataxin-3, consisting of resi-
dues 183–291, has been shown (using ThT assays) to
increase the rate of aggregation of ataxin-3, while the
addition of these residues as a soluble protein reduces
the rate of aggregation through disruption of the aggre-
gation process via competition.33,34 Together with the
results presented here, a model for QBP1 inhibition of
amyloid formation of ataxin-3 emerges in which bind-
ing to the region 183–221 prevents an interaction
between the C-terminal ﬂexible domain and other
regions of ataxin-3 that is essential for the second
polyQ-dependent stage of aggregation into amyloid.
These interactions could be mediated by the UIMs, as
suggested by Papaleo and co-workers.33 While direct
binding of QBP1 to peptides equivalent to the UIMs
of ataxin-3 could not be detected using ESI-MS, it
cannot be ruled out that the eﬀect of QBP1 on aggre-
gation of full length ataxin-3 may be mediated in part
by the UIMs, which are immediately adjacent to the
newly identiﬁed binding site.
When subjected to a blast search (BlastP) against the
human proteome (SwissProt) ataxin-3 residues 183–221
show no sequence homology to proteins other than
ataxin-3, suggestive of a unique ability of residues
183–221 of ataxin-3 to bind QBP1. Importantly, align-
ing 183–221 to the glutathione-S-transferase (GST)-
Q62 construct, against which QBP1 was originally
raised,19 also generated no hits, discounting that resi-
dues 183–221 share any homology to the GST tag used
for its selection. Residues 183–221 are not predicted to
have a high aggregation propensity as determined by
TANGO,42–44 by previous research on the central ﬂex-
ible region of ataxin-3 (residues 182–291),33,34 and by
other amyloid prediction algorithms.34
While no conformational change in ataxin-3 78Q
was observed upon the binding of QBP1, the MS
approach employed here is limited to the observation
of monomeric and early-stage oligomers in the polyQ
independent aggregation pathway. The b-sheet transi-
tion previously hypothesised to be inhibited by QBP128
is likely to occur in higher order oligomers or protoﬁ-
brils that were not observed in this investigation.11 It is
conceivable that QBP1 might prevent ataxin-3 from
transitioning into these states at later time points
through the interaction described here.
The importance of residues outside the polyQ
domain in mediating the inhibition of aggregation
138 European Journal of Mass Spectrometry 24(1)
reiterates the growing body of evidence for the import-
ance of ﬂanking domains in modulating and controlling
amyloid aggregation. The results presented here thus
have importance in terms of future design of small mol-
ecules or peptidomimetics to combat polyQ diseases.
In the quest for potential aggregation inhibitors, bind-
ing sites other than the polyQ region will require fur-
ther evaluation, including identifying and targeting
ﬂanking domains that are involved in aggregation.
A further goal to pursue is determining the residues
responsible for binding QBP1 to ataxin-3 constructs.
This would require the design and synthesis of a
range of peptides in order to pin-point the origin and
extent of speciﬁcity. Despite the fact that there is a long
way to go before satisfactory treatments are developed
for polyQ diseases, the results presented here highlight
the importance of residues 183–221 in ataxin-3 aggre-
gation, and highlight the power of MS and MS-based
approaches to identify ligand binding sites when com-
bined with a series of rationally designed truncation
variants. Moreover, the results identify a critical role
of residues 183–221 in ataxin-3 aggregation and raise
a number of fascinating questions about how and why
this sequence of the protein is critical for the conversion
of protoﬁbrils formed by self-association of the JD to
amyloid ﬁbrils into the second polyQ-dependent step of
ataxin-3 aggregation.
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